Graves' Disease News and Research

RSS

Graves’ disease, also known as toxic diffuse goiter, is the most common cause of hyperthyroidism in the United States. Hyperthyroidism is a disorder that occurs when the thyroid gland makes more thyroid hormone than the body needs.

AARDA to mark National Autoimmune Disease Awareness Month with new initiatives

March is National Autoimmune Disease Awareness Month 2013. To mark the annual event, the American Autoimmune Related Diseases Association Inc. (AARDA) is encouraging the national and local media around the country to report stories on autoimmune diseases (AD) and autoimmunity as a category of disease.

13 Feb 2013

Janssen announces U.S. prescribing information update for EDURANT tablets

Janssen Therapeutics, Division of Janssen Products, LP, announced today that the U.S. Food and Drug Administration (FDA) has approved a prescribing information update for EDURANT (rilpivirine) tablets to include 96-week pooled data from the Phase 3 ECHO and THRIVE studies, which evaluated the efficacy and safety of EDURANT for the treatment of human immunodeficiency virus type 1 (HIV-1) in antiretroviral treatment-naive adults.

11 Dec 2012

Apitope announces completion of recruitment in ATX-MS-1467 Phase I trial for MS

Apitope, the European drug discovery and development company focused on treating the underlying cause of autoimmune diseases, today announced completion of recruitment into its second Phase I clinical trial of ATX-MS-1467 in patients with multiple sclerosis (MS).

26 Nov 2012

Endocrine Society revises clinical practice guideline for management of thyroid dysfunction

The Endocrine Society has made revisions to its 2007 Clinical Practice Guideline (CPG) for management of thyroid disease during pregnancy and postpartum. The CPG provides recommendations for diagnosis and treatment of patients with thyroid-related medical issues just before and during pregnancy and in the postpartum interval.

12 Aug 2012

Positive interim data from Anthera's PEARL-SC phase 2b clinical study in systemic lupus erythematosus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced positive interim biomarker data from the PEARL-SC phase 2b clinical study in patients with systemic lupus erythematosus.

1 Dec 2011

Thyroid researcher to receive ATA's John B. Stanbury Pathophysiology Medal

Each year, the American Thyroid Association (ATA) recognizes the outstanding research contributions of one of its members to a greater understanding of thyroid physiology or the pathophysiology of thyroid disease, with its presentation of the John B. Stanbury Pathophysiology Medal at its Annual Meeting.

29 Oct 2011

New insights into causes of rheumatoid arthritis

Scientists at Mount Sinai Hospital, in collaboration with researchers at the University of Toronto, University Health Network and McGill University have obtained significant new insights into the causes of rheumatoid arthritis (RA) and other autoimmune disorders including type 1 diabetes, lupus and Graves disease.

16 Aug 2011

Endocrine Practice journal publishes new clinical guidelines on hyperthyroidism

New clinical guidelines for optimal care of patients with hyperthyroidism, a condition when the thyroid gland produces more thyroid hormone than the body needs, which affects about one percent of Americans, appear in the current issue of Endocrine Practice, the journal of the American Association of Clinical Endocrinologists.

22 Jun 2011

Mary Ann Liebert peer-reviewed journal publishes new clinical guidelines on hyperthyroidism

New clinical guidelines developed by an expert panel that include 100 evidence-based recommendations for optimal care of patients with hyperthyroidism and other causes of thyrotoxicosis are presented in the current issue of Thyroid, a peer-reviewed journal published by Mary Ann Liebert, Inc.

16 Jun 2011

ATA recognizes 4th Annual World Thyroid Day

The American Thyroid Association, in cooperation with sister international thyroid societies, the European Thyroid Association, the Asia & Oceania Thyroid Association, and the Latin American Thyroid Society, recognizes the 4th Annual World Thyroid Day, May 25, 2011.

26 May 2011

Researchers discover molecular mechanisms behind autoimmunity

Researchers from Boston University School of Medicine have discovered that human proteins with an affinity for Dermatan Sulfate have the propensity to become autoantigens. In a companion article, the researchers also found that DS physically interacts with dead cells and that the resulting DS-autoantigen complexes drive autoreactive B-1a cell responses and autoantibody production both in-vitro and in mouse models.

26 Apr 2011

Take charge of your medical tests

Whether you're healthy or ill, there are a variety of medical tests your health care team might recommend for you. A yearly checkup often includes routine tests such as blood sugar and cholesterol levels, vision and hearing assessments, tests for heart functioning and others used to monitor a chronic condition—such as a lung function test for those with asthma.

20 Dec 2010

Research may lead to new treatment strategies for Graves' disease

Researchers at the National Institutes of Health have identified a compound that prevents overproduction of thyroid hormone, a finding that brings scientists one step closer to improving treatment for Graves' disease.

2 Dec 2010

Positive results from Lithera's LIPO-102 Phase IIb clinical study for abdominal fat reduction

Lithera, Inc. today announced positive results from a Phase IIb clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.

4 Nov 2010

Lithera receives Notice of Allowance from USPTO for LIPO-102 patent application

Lithera, Inc. today announced receipt of a Notice of Allowance from the U.S. Patent and Trademark Office for a patent application broadly covering compositions and methods of use associated with LIPO-102, its novel injectable combination of salmeterol xinafoate (SX) and fluticasone propionate (FP) for selective, non-ablative fat reduction.

13 Oct 2010

Anthera initiates PEARL-SC Phase 2b study of A-623 for lupus

Anthera Pharmaceuticals, Inc., a biopharmaceutical company developing drugs to treat serious diseases associated with inflammation, today announced it has initiated PEARL-SC, the Phase 2b study of A-623, a novel inhibitor of B-Cell Activating Factor, or BAFF, for the treatment of Systemic Lupus Erythematosus (lupus). Lupus patients suffer from a chronic autoimmune disease, which often leads to severe skin rash, fatigue, joint pain, major organ complications, and cardiovascular disease.

30 Jul 2010

UB study: Vietnam veterans exposed to Agent Orange are more likely to develop Graves' disease

Vietnam War-era veterans exposed to Agent Orange appear to have significantly more Graves' disease, a thyroid disorder, than veterans with no exposure, a new study by endocrinologists at the University at Buffalo has shown.

29 Jun 2010

ATA members raise concern about reduction in dietary iodine intake

Following publication of an article in the February 18 issue of the New England Journal of Medicine (Vol. 362 No. 7 pp 590-599) by Bibbins-Domingo, et al. that projected the effect of moderate dietary salt reductions on future cardiac disease rates, several members of the American Thyroid Association, concerned about the subsequent potential reduction in availability of iodine, have responded with a letter in the current issue of the NEJM (Vol. 362 No. 23 pp 2224-2226).

15 Jun 2010

Personalized treatments for thyroid disorders to be presented at ATA meeting

Internationally recognized thyroid disease experts will meet to discuss "Thyroid Disorders in the Era of Personalized Medicine" May 13 - 16 in Minneapolis, Minnesota at the American Thyroid Association's (ATA) (www.thyroid.org) Spring Meeting to be held at the Minneapolis Hyatt Regency Hotel.

11 May 2010

Positive results from Phase IIa clinical study of LIPO-102

Lithera, Inc. today announced positive results from a Phase IIa clinical study of LIPO-102, its novel injectable combination of salmeterol xinafoate and fluticasone propionate for selective, non-ablative fat reduction. LIPO-102 was well-tolerated when administered weekly for 8 weeks into the subcutaneous abdominal fat of healthy subjects.

6 May 2010